Multiple Sclerosis Drug Market Segmentation:
Disease Type Segment Analysis
The relapsing-remitting MS (RRMS) segment is projected to dominate the market, with the highest share of 69.5% by the end of 2035. The segment’s growth is highly fueled by an increase in the treatment integration rates, as well as an upsurge in the prevalence globally. This segment is considered the most common MS subtype, and therefore, RRMS patients demand constant disease-based therapies to prevent delayed progression and relapses. In addition, the segment’s upliftment is also driven by cutting-edge monoclonal antibodies, such as Roche’s Ocrevus, along with oral therapy, thus demonstrating reduction in relapse during clinical studies.
Drug Class Segment Analysis
Monoclonal antibodies segment is expected to hold the second-largest market share of 40.5% during the forecast period. The segment’s growth is effectively driven by managing disability progression, along with superior efficiency in relapse prevention. Besides, the segment also propels from stretched dosage intervals, constituting half a year for Ocrevus, and robust payer coverage.
Route of Administration Segment Analysis
The oral segment market is anticipated to account for the third-largest share of 33.7% by the end of the forecast timeline. This particular therapy is positively uplifting the overall market, owing to convenience and superior patient adherence, with the inclusion of notable agents, such as Biogen's Vumerity. In addition, the segment readily benefits from an expansion in Medicare Part D coverage. Besides, advanced oral BTK inhibitors, such as Merck’s evobrutinib, provide targeted immunomodulation with regular dosage, thereby suitable for the overall segment.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegments |
|
Disease Type |
|
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
